Nov2022
CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials
• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed
Oct2022
Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73)
Parkinson’s Disease: A new path toward restoring key neurodegenerative functions. Discover our analysis of a clinical trial highlighting a potential molecular mechanism of blarcamesine! (ANAVEX®2-73) Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows. Cambridge, MA, USA and Paris, France – Ariana Pharma, the leading Al-driven precision medicine company, […]
Jul2022
Ariana Pharma strengthens management team with appointments of VP Business Development and Chief Financial Officer
Paris, France and Cambridge, MA, USA, July 26th, 2022 – Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. […]